License covers tumor treatment that targets a specific novel cancer biomarker.



Senetek inked an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland, for the exclusive rights to a tumor treatment using an RNAi-based therapeutic technology for the potential use against a broad range of cancers.


This technology, which specifically targets a novel cancer biomarker, was developed by the Institute in cooperation with the department of neurosurgery and neurotraumatology at the University of Medical Sciences in Poznan. Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.








This site uses Akismet to reduce spam. Learn how your comment data is processed.